Literature DB >> 15564983

Masked hypertension: how can the condition be detected?

Paolo Palatini1.   

Abstract

Recent evidence demonstrates that masked hypertension is a significant predictor of cardiovascular disease, but the problem for clinical practice is how to identify these patients. Furthermore, the prevalence of masked hypertension in the general population or in subjects with transient blood pressure elevation is still unknown. Data obtained in several cross-sectional studies have demonstrated large differences in the prevalence of masked hypertension, with prevalence rates from a low of 8% to a high of 49%. Two population-based studies performed in Italy and in Japan report prevalence of 9% and of 13.4%, respectively. A 49% frequency of masked hypertension has been found among subjects with transiently elevated clinic blood pressure. Several factors can selectively raise ambulatory blood pressure including age, sex, smoking, alcohol use, contraceptive use in women, and sedentary habits. Reactivity to daily life stressors and behavioural factors are other important determinants of ambulatory blood pressure. On the basis of the available evidence, masked hypertension should be searched for in individuals who are more likely to have this condition or are at increased risk of cardiovascular complications including diabetic individuals and subjects with kidney disease. Further research is needed to determine whether the use of ambulatory blood pressure monitoring is cost-effective in these subjects.

Entities:  

Mesh:

Year:  2004        PMID: 15564983     DOI: 10.1097/00126097-200412000-00005

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  11 in total

Review 1.  Masked hypertension: a common but insidious presentation of hypertension.

Authors:  D W McKay; Martin G Myers; Peter Bolli; Arun Chockalingam
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

2.  The international intravitreal bevacizumab safety survey.

Authors:  F Ziemssen; S Grisanti; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

3.  Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration.

Authors:  A Sengul; R Rasier; C Ciftci; O Artunay; A Kockar; H Bahcecioglu; E Yuzbasioglu
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

Review 4.  Diagnosis and management of patients with white-coat and masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Gino Seravalle; Guido Grassi
Journal:  Nat Rev Cardiol       Date:  2011-08-09       Impact factor: 32.419

Review 5.  Ambulatory blood pressure and cardiovascular risk in chronic kidney disease.

Authors:  Paolo Palatini
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369

Review 6.  Masked Hypertension: How to Identify and When to Treat?

Authors:  Damiano Rizzoni
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-04-04

7.  Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris.

Authors:  Ahmet Bacaksiz; Ercan Erdogan; Osman Sonmez; Emrah Sevgili; Abdurrahman Tasal; Nahide Onsun; Bugce Topukcu; Beytullah Kulaç; Omer Uysal; Omer Goktekin
Journal:  Med Sci Monit       Date:  2013-06-26

Review 8.  Masked hypertension definition, impact, outcomes: a critical review.

Authors:  Dimitris P Papadopoulos; Thomas K Makris
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

9.  Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels.

Authors:  Dimitris P Papadopoulos; Despina Perrea; Costas Thomopoulos; Elias Sanidas; Maria Daskalaki; Urania Papazachou; V Votteas; Thomas Makris
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

10.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.